Bain Capital Exits Kioxia After AI-Fueled Valuation Surge 
Telenor to Buy Controlling Stake in Bahnhof in $630 Million Broadband Deal 
Samsung Chairman Lee Jae-yong Expected to Meet Nvidia CEO Jensen Huang on AI and Chip Partnership 
BHP Faces Port Hedland Strike Threat as Iron Ore Export Risks Grow 
SK Hynix’s $28 Billion U.S. Share Sale Draws Massive Demand Amid AI Chip Boom 
Kitron Q2 Revenue Beats Estimates as Defense Demand Lifts Growth 
OpenAI Executive Fidji Simo to Step Down Amid Health Challenges Ahead of IPO 
Goldman AM Sees Strong Buyout Opportunities in Japan, South Korea and Australia 
Oil and LNG Tankers Turn Back as Strait of Hormuz Security Risks Escalate 
Oppenheimer Sees CNH Industrial as Top 2026 Agriculture Stock Pick on Dealer Consolidation Strategy 
Morgan Stanley Names Marks & Spencer Top European Retail Pick, Sees Strong Upside 
Elon Musk Says Anthropic Leads AI Race as Claude Models Challenge OpenAI 
Chinese Chip Stocks Jump as Apple Reportedly Tests CXMT Memory Chips for China Devices 
Fast Retailing Raises Full-Year Forecast After Uniqlo Owner Beats Q3 Profit Estimates 
AstraZeneca Shares Sink After Wainua Trial Misses Key Heart Disease Goal 
Nvidia Invests $500M in Firmus Technologies Ahead of Planned ASX IPO 
CRANBURY, N.J., April 26, 2018 -- Amicus Therapeutics (Nasdaq:FOLD) today announced a conference call and live audio webcast on Tuesday, May 8, 2018 at 8:30 a.m. ET to discuss financial results for the first quarter ended March 31, 2018.
The call will be hosted by John F. Crowley, Chairman and Chief Executive Officer. He will be joined on the call by additional members of the Amicus management team. Interested participants and investors may access the conference call by dialing 877-303-5859 (U.S./Canada) or 678-224-7784 (international), conference ID: 6678368.
A live audio webcast can also be accessed via the Investors section of the Amicus Therapeutics corporate website at http://ir.amicusrx.com/, and will be archived for 30 days. Web participants are encouraged to go to the website 15 minutes prior to the start of the call to register, download, and install any necessary software.
A telephonic replay of the call will be available for seven days beginning at 11:30 a.m. ET on May 8, 2018. Access numbers for this replay are 855-859-2056 (U.S./Canada) and 404-537-3406 (international); conference ID: 6678368.
About Amicus Therapeutics
Amicus Therapeutics (Nasdaq:FOLD) is a global, patient-centric biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases. The cornerstone of the Amicus portfolio is migalastat, an oral precision medicine for people living with Fabry disease who have amenable genetic mutations. Migalastat is currently approved under the trade name Galafold™ in the European Union, with additional approvals granted and pending in several geographies. The lead biologics program in the Amicus pipeline is ATB200/AT2221, a novel, late-stage, potential best-in-class treatment paradigm for Pompe disease. The Company is committed to advancing and expanding a robust pipeline of cutting-edge, first- or best-in-class medicines for rare metabolic diseases.
CONTACTS:
Investors/Media:
Amicus Therapeutics
Sara Pellegrino, IRC
Vice President, Investor Relations & Corporate Communications
[email protected]
(609) 662-5044
Media:
Pure Communications
Jennifer Paganelli
[email protected]
(347) 658-8290
FOLD–G
